Bone quality and osteonecrosis of the jaw induced by bisphosphonates;Qualité osseuse et ostéonécrose des maxillaires due aux bisphosphonates

Medecine Buccale Chirurgie Buccale

Volumn 18, Issue 1, 2012, Pages 9-15

  Hémar, Julie ^a,b,c   Sauvigné, Thierry ^b   Bodard, Anne Gaëlle ^d   Boivin, Georges ^c  

^a UNIVERSITÉ DE LYON   (France)

^b CENTRE HOSPITALIER LYON SUD   (France)

^c INSERM   (France)

^d CENTRE LÉON BÉRARD   (France)

Author keywords

Bisphosphonates; Hardness tests; Jaw; Microradiography; Osteonecrosis

Indexed keywords

EID: 84880287785     PISSN: 12732761     EISSN: 21051011     Source Type: Journal    
DOI: 10.1051/mbcb/2011144     Document Type: Article

References (30)

1. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:115-7.
2. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62:527-34.
3. Santini D, Vincenzi B, Dicuonzo G, Avvisati G, Massacesi C, Battistoni F, Gavasci M, Rocci L, Tirindelli MC, Altomare V, Tocchini M, Bonsignori M, Tonini G. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 2003;9:2893-7.
4. Corrado A, Santoro N, Cantatore FP. Extra-skeletal effects of bisphosphonates. Joint Bone Spine 2007;74:32-8.
5. Clézardin P, Ebetino FH, Fournier PG. Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity. Cancer Res 2005;65:4971-4.
6. Jimenez-Soriano Y, Bagan JV. Bisphosphonates, as a new cause of drug-induced jaw osteonecrosis: an update. Med Oral PatolOral Cir Bucal 2005;10(Suppl 2):E88-91.
7. Purcell PM, Boyd IW. Bisphosphonates and osteonecrosis of the jaw. Med J Aust 2005;182:417-8.
8. Bauss F, Dempster DW. Effects of ibandronate on bone quality: preclinical studies. Bone 2007;40:265-73.
9. Meunier PJ, Boivin G. Bonemineraldensityreflectsbonemassbut also the degree of mineralization of bone: therapeutic implications. Bone 1997;21:373-7.
10. Marx RE. Oral and intravenous bisphosphonate-induced osteonecrosis of the jaws. History, etiology, prevention, and treatment. Quintessence Publishing Co Inc. Chicago, 2007.
11. Bagan JV, Murillo J, Jimenez Y, Poveda R, Milian MA, Sanchis JM, Silvestre FJ, Scully C. Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. J Oral Pathol Med 2005;34:120-3.
12. Merigo E, Manfredi M, Meleti M, Guidotti R, Ripasarti A, Zanzucchi E, D'Aleo P, Corradi D, Corcione L, Sesenna E, Ferrari S, Poli T, Bonaninil M, Vescovi P. Bone necrosis of thejaws associated with bisphosphonate treatment: a report of twenty-nine cases. Acta Biomed 2006;77:109-17.
13. Migliorati CA, Siegel MA, Elting LS. Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncol 2006;7:508-14.
14. Shane E, Goldring S, Christakos S, Drezner M, Eisman J, Silverman S, Pendrys D. Osteonecrosis of the jaw: more research needed. J Bone Miner Res 2006;21:1503-5.
15. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos E, Dimopoulos MA. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005;23:8580-7.
16. Kim T, Hong J, Park E, Kim S. Vascular endothelial growth factor gene polymorphism is associated with increased risk of femoral head osteonecrosis. J Bone Miner Res 2006;21(Suppl 1):243.
17. Woeller A, Gering A, Brix M, Bettega G, Lebeau J. Ostéonécrose des maxillaires sous bisphosphonates: cinq cas. Rev Stomatol Chir Maxillofac 2006;107:417-22.
18. Boivin G, Meunier PJ. Histomorphometric methods applied to bone (pp. 137-56). In Histology of ancient human bone. Grupe G, Garland AN Ed., Springer, Berlin, 1993.
19. Boivin G, Meunier PJ. The degree of mineralization of bone tissue measured by computerized quantitative contact microradiography. Calcif Tissue Int 2002;70:503-11.
20. Boivin G, Meunier PJ. Methodological considerations in measurement of bone mineral content. Osteoporos Int 2003;14 (Suppl 5):22-8.
21. Boivin G, Bala Y, Doublier A, Farlay D, Ste-Marie LG, Meunier PJ, Delmas PD. The role of mineralization and organic matrix in the microhardness of bone tissue from controls and osteoporotic patients. Bone 2008;43:532-8.
22. Marx RE, Sawatari Y, Fortin M, Broumand V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of thejaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63:1567-75.
23. Wood J, Bonjean K, Ruetz S, Bellahcène A, Devy L, Foidart JM, Castronovo V, Green JR. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002;302:1055-61.
24. Kaczmarczyk-Sedlak I, Janiec W. Effects of catecholamines on blood pressure in the long bone marrow cavity in rats with bisphosphonate-induced osteopetrosis. Pharmacol Rep 2005;57:623-34.
25. Germanier Y, Carrel JP, AbiNajm S, Samson J. Ostéopétrose ou maladie des os de marbre - 3. Manifestations stomatologiques. Med Buccale Chir Buccale 2007;13:37-48.
26. Boivin GY, Chavassieux PM, Santora AC, Yates J, Meunier PJ. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 2000;7:687-94.
27. Badros A, Weikel D, Salama A, Goloubeva O, Schneider A, Rapoport A, Fenton R, Gahres N, Sausville E, Ord R, Meiller T. Osteonecrosis ofthejawin multiple myeloma patients: clinicalfeatures and risk factors. J Clin Oncol 2006;24:945-52.
28. Sanna G, Zampino MG, Pelosi G, Nolè F, Goldhirsch A. Jaw avascular bone necrosis associated with long-term use of bisphosphonates. Ann Oncol 2005;16:1207-8.
29. Leite AF, Figueiredo PT, Melo NS, Acevedo AC, Cavalcanti MG, Paula LM, Paula AP, Guerra EN. Bisphosphonate-associated osteonecrosis of thejaws. Report of a case and literature review. OralSurg Oral Med Oral Pathol Oral Radiol Endod 2006;102:14-21.
30. Burr DB. Targeted and nontargeted remodeling. Bone 2002;30:2-4.